These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Natalizumab. Elan/Biogen.
    Author: Elices MJ.
    Journal: Curr Opin Investig Drugs; 2003 Nov; 4(11):1354-62. PubMed ID: 14758775.
    Abstract:
    Natalizumab is a humanized monoclonal antibody to alpha 4 beta 1 integrin (VLA-4) currently under development by Elan and Biogen for the treatment of Crohn's disease and multiple sclerosis. Phase II trials in both indications have been completed, and by December 2002 phase III trials in Crohn's disease and multiple sclerosis had been initiated.
    [Abstract] [Full Text] [Related] [New Search]